Innovative Therapeutic Approaches in Congenital Myasthenic Syndromes

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Congenital myasthenic syndromes (CMS) are rare genetic disorders affecting neuromuscular transmission.
• Traditional treatments for CMS have limitations, necessitating exploration of novel therapeutic strategies.

Purpose of the Study:

• To present real-world clinical follow-up data on patients with congenital myasthenic syndromes (CMS).
• To evaluate the efficacy of innovative drugs in managing CMS patients with diverse genetic mutations and pathophysiological profiles.

Main Methods:

• Six patients with genetically confirmed CMS and varying mutation types were recruited.
• Clinical progress was assessed using clinical evaluations, electromyography, and genetic studies.
• Patients received innovative drugs not typically indicated for neurological conditions.

Main Results:

• All six patients demonstrated clear clinical improvement following treatment with innovative drugs.
• The study included patients with diverse CMS subtypes, including slow-channel, fast-channel, and low-expressor syndromes.
• The observed outcomes suggest a positive response to novel therapeutic interventions.

Conclusions:

• Innovative drug therapies, beyond pyridostigmine, can significantly improve outcomes for patients with congenital myasthenic syndromes.
• These findings underscore the potential of repurposing non-neurological drugs for managing this orphan disease.
• Class IV evidence supports the effectiveness of these innovative treatments in CMS management.